Clinical Trials Directory

Trials / Completed

CompletedNCT04167371

Treament of Rumination

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
32 (actual)
Sponsor
Hospital Universitari Vall d'Hebron Research Institute · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Background. Rumination syndrome is characterized by effortless recurrent regurgitation of recently ingested food into the mouth, with consequent expulsion or re-chewing and swallowing. In a previous study we showed that rumination is produced by an unperceived, somatic response to food ingestion. We developed an original biofeedback technique based on electromyography-guided control of abdominothoracic muscular activity. In a randomized, placebo-controlled trial we demonstrated the superiority of biofeedback over placebo for the treatment of rumination. However, the technique is technically complex and unpractical. Aim. To prove the efficacy of a simplified biofeedback technique for the treatment of rumination. Selection criteria. Rumination after meal ingestion. Intervention. Patients will be randomized into biofeedback in placebo groups. Three sessions of either biofeedback or placebo intervention will be performed after ingestion of a probe meal during the first 3 weeks of the 4 weeks intervention period. Biofeedback: patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period. Placebo: abdominal and thoracic perimeter will be recorded but not shown to the patient and a pill of placebo containing 0.5 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period. Primary Outcome Measure: Number of rumination events measured by electromyography in response to the challenge meal before and after treatment. Secondary Outcome Measures: * Number of self perceived rumination events measured by questionnaires administered daily for 10 days will before and after treatment. * Associated abdominal symptom measured by questionnaires administered daily for 10 days before and after treatment. * Follow up: number of self perceived rumination events measured at 1, 3 and 6 months after treatment.

Conditions

Interventions

TypeNameDescription
BEHAVIORALBiofeedbackThree sessions by biofeedback will be performed during the first 3 weeks of the intervention period. In each session patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
DIETARY_SUPPLEMENTPlaceboThree sessions will be performed during the first 3 weeks of the intervention period. In each session abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.

Timeline

Start date
2019-12-02
Primary completion
2020-10-30
Completion
2022-02-01
First posted
2019-11-18
Last updated
2022-02-14

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT04167371. Inclusion in this directory is not an endorsement.